Results 161 to 170 of about 3,748 (212)

Real-World Effectiveness and Safety of Eliglustat in Adult Patients with Gaucher Disease Type 1: A Multicenter Retrospective Study in China. [PDF]

J Clin Med
Zhou Y, Hao Z, Zhuang Q, Han B.
europepmc   +1 more source

Isolation and characterization of secretory vesicles from bovine neurophyses [PDF]

, 1980
Dartt, D., Gratzl, Manfred, Thorn, N. A., Torp-Pedersen, C., Treiman, M.   +4 more
core  

AAV delivery of GBA1 suppresses α-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models. [PDF]

PLoS One
Okai T, Sato S, Deshpande M, Matsumoto SI, Nakayama M, Yamamoto S, Strack-Logue B, Hioki T, Tanaka M, Proetzel G.   +9 more
europepmc   +1 more source

Novel Strategies against Hepatocellular Carcinoma through Lipid Metabolism. [PDF]

Oncol Res
Yang Y, Zhao P, Chen H, Tu Y, Zhou Y, Liu X, Sreang L, Zhou Z, Tu J.   +8 more
europepmc   +1 more source

Impact of Sinbaglustat on Neurons of the Medial Nucleus of the Trapezoid Body in a Murine Model of Human G_M1-Gangliosidosis. [PDF]

J Clin Med
Jubran L, Wannemacher R, Baumgärtner W, Felmy F, Steiner MA, Leitzen E, Kladisios N.   +6 more
europepmc   +1 more source

Association of Sporadic and Genetic Parkinson's Disease with Cancer: Insights from the PPMI Cohort. [PDF]

Genes (Basel)
Sfikas E, Koros C.
europepmc   +1 more source

Diet, β-glucocerebrosidase deficiency, and Parkinson's disease. [PDF]

J Lipid Res
Shayman JA.
europepmc   +1 more source

Protective Effect of the LRRK2 Kinase Inhibition in Human Fibroblasts Bearing the Genetic Variant GBA1 K198E: Implications for Parkinson's Disease. [PDF]

Neuromolecular Med
Perez-Abshana LP, Mendivil-Perez M, Velez-Pardo C, Jimenez-Del-Rio M.   +3 more
europepmc   +1 more source

Therapeutic Effects of Nizubaglustat in a Mouse Model of GM2 Gangliosidosis. [PDF]

J Inherit Metab Dis
Landskroner K, Singh K, Mitchell M, Walia JS.   +3 more
europepmc   +1 more source